In a breast and pancreatic cancer study, tumor-derived granulocyte-stimulating factor induced alterations in the development of CD141+ DC, which were associated with impaired CD8+ T cell responses and correlated with poor clinical outcomes (86). The gene discussed is CD8A; the disease is neoplasm.